araag2/HINT huggingface dataset:
Clinical trial NCT00485589 (phase 3, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, ocrelizumab, placebo
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    based on analysis of results and consideration of available treatments, the overall benefit to
    risk profile of ocrelizumab was not favorable in ra.
  
Eligibility criteria:

        Inclusion criteria:

          -  Age ≥ 18

          -  Rheumatoid arthritis for 3 months-5 years

          -  Naive to methotrexate

          -  If receiving steroids or NSAIDs, must be on a stable dose for 4 weeks prior to
             baseline

        Exclusion criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease other than RA

          -  Prior receipt of any biologic therapy for RA

          -  Concurrent treatment with any DMARD
Clinical trial NCT00251693 (phase 3, status: completed)
Conditions: esophagitis, reflux, esophagitis, peptic
ICD codes: K21.9, K21.00, K21.01, B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: dexlansoprazole mr, dexlansoprazole mr, lansoprazole
SMILES: CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1, CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject must have endoscopically confirmed erosive esophagitis as defined by the Los
             Angeles (LA) Classification Grading System (A-D)

        Exclusion Criteria:

          -  Subject has a positive Campylobacter-like organisms (CLO) test for Helicobacter (H.)
             pylori.

          -  Use of prescription or non-prescription proton pump inhibitors (PPIs), histamine (H2)
             receptor antagonists or sucralfate, drugs with significant anticholinergic effects,
             misoprostol or prokinetics

          -  Use of antacids [except for study supplied Gelusil®]

          -  Need for continuous anticoagulant therapy (blood thinners)

          -  Endoscopic Barrett's esophagus and/or definite dysplastic changes in the esophagus

          -  History of dilatation of esophageal strictures, other than Schatzki's ring (a ring of
             mucosal tissue near the lower esophageal sphincter)

          -  Current or historical evidence of Zollinger-Ellison syndrome or other hypersecretory
             condition.

          -  History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer.

          -  Acute upper gastrointestinal hemorrhage within 4 weeks of the screening endoscopy
Clinical trial NCT00151502 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnostic evidence of probable Alzheimer's disease consistent with NINCDS/ADRDA and
             DSM IV criteria.

          -  Subject's Mini-Mental Status Examination Score (MMSE) must be in the range of 13 - 25
             (inclusive) at Screening.

        Exclusion Criteria:

          -  Subjects with dementia due to causes other than Alzheimer's disease.

          -  Any condition, which, in the investigator's judgment might increase the risk to the
             subject or decrease the reliability of the data required to meet the objectives of the
             study.
Clinical trial NCT00095030 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: muraglitazar
SMILES: COC1=CC=C(OC(=O)N(CC(O)=O)CC2=CC=C(OCCC3=C(C)OC(=N3)C3=CC=CC=C3)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not
             greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to
             screening

          -  HbA1c >or = 7% and < or = 10%

          -  Fasting c-peptide > or = 1.0 umol

          -  Body Mass Index < or = 41 kg/m2

          -  Mean serum triglycerides < or = 600 mg/dl
Clinical trial NCT00471328 (phase 3, status: completed)
Conditions: gastrointestinal stromal tumors
ICD codes: C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, C49.A9
Drugs: nilotinib
SMILES: CC1=CN(C=N1)C1=CC(NC(=O)C2=CC=C(C)C(NC3=NC=CC(=N3)C3=CN=CC=C3)=C2)=CC(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion criteria (Core Phase):

          -  Age ≥18 years

          -  Radiological confirmation of disease progression during imatinib and sunitinib therapy
             OR intolerance to imatinib and/or sunitinib

          -  At least one measurable site of disease on CT/MRI scan

          -  Physically fit even if not able to work

          -  Normal organ, electrolyte, and bone marrow function

        Inclusion criteria (Extension Phase):

          -  Patients whose tumors had progressed on the control arm and had crossed over to the
             nilotinib arm.

          -  The study was stopped due to meeting the primary efficacy endpoint of PFS at the
             interim analysis.

          -  Patients who were still being treated at the close of the Core study on the control
             arm or nilotinib arm (whose tumors have not progressed at the time of the end of the
             Core study).

          -  Patients must have had documented, confirmed stable, partial or complete response as
             defined by the RECIST criteria at the time of entry into the Extension study with the
             exception of patients who had progressed on the control arm.

        Exclusion criteria (Core Phase):

          -  Previous treatment with nilotinib or any other drug in this class or other targeted
             therapy

          -  Treatment with any cytotoxic and/or investigational cytotoxic drug ≤ 4 weeks prior to
             study entry

          -  Impaired cardiac function

          -  Use of coumarin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)

          -  Women who are pregnant or lactating

        Exclusion criteria (Extension Phase):

          -  Use of other anticancer treatments or investigational drugs (with exception of the
             study drugs)

          -  Patients with a history of noncompliance with study drug treatment in the Core study
             protocol.

        Other protocol-defined inclusion/exclusion criteria applied
Clinical trial NCT00395343 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, comparator : placebo (unspecified)
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has type 2 diabetes mellitus

          -  Patient is poorly controlled while on insulin or insulin and metformin

        Exclusion Criteria:

          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

          -  Patient is taking oral antidiabetic agents other than metformin during the past 3
             months

          -  Patient is currently on treatment with daily use of pre-prandial short-acting or
             rapid-acting insulin
Clinical trial NCT00668525 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: escitalopram, placebo, escitalopram
SMILES: CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must meet Diagnostic and Statistical Manual, Fourth Edition, Text Revision
             (DSM-IV-TR) diagnostic criteria for Major Depressive Disorder.

          -  The patient's current depressive episode must be at least 8 weeks in duration.

        Exclusion Criteria:

          -  Women who are pregnant, women who will be breastfeeding during the study, and women
             with childbearing potential who are not practicing a reliable method of birth control.

          -  Patients with a history of meeting DSM-IV-TR criteria for: a. any manic or hypomanic
             episode; b. schizophrenia or any other psychotic disorder; c. obsessive-compulsive
             disorder.

          -  Patients who are considered a suicide risk

          -  Patients with a history of seizures (including seizure disorder), stroke, significant
             head injury, central nervous system tumors, or any other condition that predisposes
             patients to a risk for seizure.
Clinical trial NCT00481247 (phase 3, status: completed)
Conditions: myeloid leukemia, chronic
ICD codes: C92.11, C92.12, C92.21, C92.22, C92.10, C92.20
Drugs: dasatinib, imatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female, aged 18 years and older

          -  Chronic phase, Philadelphia Chromosome-positive chronic myeloid leukemia (CML)

          -  Eastern Cooperative Oncology Group Performance Status score of 0-2

        Key Exclusion Criteria:

          -  Pleural Effusion

          -  Uncontrolled cardiovascular disease

          -  Significant bleeding disorder unrelated to CML

          -  Prior treatment with interferon/imatinib/dasatinib/anti-CML systemic treatments except
             anagrelide/hydroxyurea
Clinical trial NCT00390520 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with T2DM, diagnosed at least 6 weeks prior to visit 1, who have had no
             treatment with oral antidiabetic agents for at least 12 weeks prior to study entry
             (visit 1) and no treatment with oral antidiabetic agents at any time in the past for >
             3 consecutive months

          -  >/= 18 years

          -  Body mass index in the range of 22-35 kg/m2

          -  HbA1c </=7.5%

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Acute metabolic diabetic complications

          -  Evidence of significant diabetic complications

          -  Insulin treatment within the past 6 months

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01517412 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: lixisenatide (ave0010), metformin
SMILES: [V].[H][C@](C)(O)[C@]([H])(N=C(O)CN=C(O)[C@]([H])(CCC(O)=O)N=C(O)CN=C(O)[C@@]([H])(N)CC1=CN=CN1)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CCSC)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(O)=N)C(O)=NCC(O)=NCC(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=NCC(O)=N[C@@]([H])(C)C(=O)N1CCC[C@@]1([H])C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N)[C@@]([H])(C)CC)[C@@]([H])(C)O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Participants with type 2 diabetes mellitus, diagnosed for at least 1 year before
             screening visit

          -  Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior
             to screening visit.

        Exclusion criteria:

          -  Screening HbA1c < 7.0% and > 10.0%

          -  Fasting plasma glucose at screening > 250 mg/dL (> 13.9 mmol/L)

          -  Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months
             prior to screening, previous use of insulin

          -  Participants who usually did not eat breakfast

          -  Type 1 diabetes mellitus

          -  Body Mass Index (BMI) ≤ 20 kg/m^2 and > 40 kg/m^2

          -  Pregnancy or lactation, women of childbearing potential with no effective
             contraceptive method

          -  Amylase and/or lipase > 3 times the upper limit of the normal laboratory range ( ULN)
             at screening

          -  Alanine aminotransferase (ALT) > 3 ULN at screening

          -  Calcitonin ≧ 20 pg/ml (5.9 pmol/L) at screening

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.

          -  Personal or immediate family history of medullary thyroid cancer (MTC) or genetic
             conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes)

          -  Any contra-indication related to metformin

          -  Any previous treatment with lixisenatide

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT01153347 (phase 3, status: completed)
Conditions: major depressive disorder, depression
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: tc-5214, placebo
SMILES: CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed and dated informed consent before initiation of any study-related
             procedures.

          -  The patient must have a clinical diagnosis of major depressive disorder (MDD) with
             inadequate response to no more than one antidepressant.

          -  Outpatient status at enrollment and randomization.

        Exclusion Criteria:

          -  Patients with a lifetime history of bipolar disorder, psychotic disorder or
             post-traumatic stress disorder.

          -  Patients with a history of suicide attempts in the past year and/or seen by the
             investigator as having a significant history of risk of suicide or homicide.

          -  History of renal insufficiency or impairment or conditions that could affect
             absorption or metabolism of investigational product.
Clinical trial NCT00505778 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: mesalamine once-daily, mesalamine twice-daily
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Documented history of ulcerative colitis that has been successfully maintained in
             remission for at least 3 months prior to study entry

          -  At least one flare in the past 18 months

          -  Utilizing a stable maintenance dose of oral Asacol of 1.6 g/day up to 2.4 g/day
             (stable dose is defined as the same dose for the past 3 months)

          -  Females must be postmenopausal or surgically sterile or have a negative urine
             pregnancy test and practice acceptable contraception

        Exclusion Criteria:

          -  History of or current renal disease

          -  History of hepatic disease

          -  History of allergy or hypersensitivity to salicylates, aminosalicylates

          -  Treatment with immunomodulatory therapy, biologic therapy or corticosteroids within 90
             days of screening

          -  Received any antidiarrheals, antispasmodics, or antibiotic within 1 month of screening
Clinical trial NCT00288483 (phase 3, status: terminated)
Conditions: hypercholesterolemia, combined hyperlipidemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: policosanol
SMILES: [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
Eligibility criteria:

        Inclusion Criteria:

          -  Isolated hypercholesterolaemia or combined hyperlipidaemia with mean LDL values at
             Visits 2 and 3 of > 150 mg/dl for patients with no or one risk factor (other than
             known coronary artery disease) or 150-189 mg/dl for patients with two or more risk
             factors for the development of cardiovascular events (males > 45 years of age, females
             > 55 years of age or postmenopausal), known coronary artery disease, uncontrolled
             hypertension > 140 mm Hg systolic, HDL level < 35 mg/dl (mean of the values of visits
             2 and 3), current cigarette smoking of > 10 cigarettes/day, obesity with BMI > 30
             kg/m², family history of coronary heart disease),

          -  male or female patients aged from 18 to 80 years,

          -  negative pregnancy test for woman of childbearing potential,

          -  no communication problems with the investigator,

          -  availability of a signed informed consent to participate in the trial, for medical
             data to be recorded and made available to a third party.

        Exclusion Criteria:

          -  - known hypersensitivity to any component of the drug,

          -  myocardial infarction less than one year before clinical trial inclusion,

          -  PTCA or CABG less than one year before clinical trial inclusion,

          -  unstable angina pectoris,

          -  hypothyroidism,

          -  diabetes mellitus,

          -  acute inflammatory diseases,

          -  severe gastrointestinal diseases,

          -  triglycerides values > 500 mg/dl at Visit 2 or 3,

          -  use of oral systemic corticosteroids, anticoagulants or other lipid-lowering drugs,

          -  serious diseases or circumstances not allowing the patient's participation in the
             trial (e.g. malignoma, alcoholism or drug abuse, severe kidney and liver diseases),

          -  pregnancy, lactation and women of childbearing potential without employing a safe
             contraception method,

          -  participation in a clinical trial within the last 30 days before Visit 1,

          -  repeated inclusion in the present clinical trial.
Clinical trial NCT00411099 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: agomelatine, placebo
SMILES: COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Major Depressive Disorder, single or recurrent episode, according to
             DSM-IV criteria

          -  HAM-D17 total score > or = 22 at Screening and Baseline

          -  CGI-Severity score > or = 4 at Screening and Baseline

          -  Only patients who complete the core protocol are eligible to participate in the
             Open-Label Extension Phase

        Exclusion Criteria:

          -  History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating
             disorder, or obsessive compulsive disorder

          -  Any current Axis I disorder other than major depressive disorder which is the focus of
             treatment

          -  Substance or alcohol abuse in the last 30 days, dependence in the last 6 months

          -  Concomitant psychotropic medication, including herbal preparations and melatonin

          -  Psychotherapy of any type

          -  Female patients of childbearing potential who are not using effective contraception

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00554619 (phase 3, status: completed)
Conditions: pulmonary arterial hypertension, hypertension, pulmonary
ICD codes: I27.21, I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: gsk1325760a
SMILES: COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who complete the 24-week administration of the Phase II/III study (Study
             No.AMB107816)

          -  Subjects who are assessed that the long-term extension administration of GSK1325760A
             is appropriate in the judgement of the investigator or subinvestigator

          -  Subjects who request the long-term extension administration of GSK1325760A, and agree
             to newly sign the informed consent form

        Exclusion Criteria:

          -  Subjects who have been withdrawn from the Phase II/III study.

          -  Female subjects who wish to become pregnant.

          -  Treatment with other PAH medication is needed.

          -  A worsening of 2 or more levels of the WHO Functional Classification (see Appendix
             2.1) comparing with the baseline of Phase II/III study (Study No.AMB107816).

          -  Worsening of right ventricular failure (e.g. as indicated by increased jugular venous
             pressure, new/worsened hepatomegaly, ascites, or peripheral edema) during Phase II/III
             study (Study No.AMB107816).

          -  Rapidly progressing cardiac, hepatic or renal failure during Phase II/III study (Study
             No.AMB107816).

          -  Participation to the long-term extension study is considered as inappropriate in the
             judgment of the investigator or subinvestigator.
Clinical trial NCT00484939 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, ≥ 70 years of age.

          -  Cancer of the colon or rectum.

          -  Metastatic disease diagnosed ≤ 6 months before enrollment.

          -  ≥ 1 measurable metastatic lesion.

        Exclusion Criteria:

          -  Adjuvant anti-vascular endothelial growth factor (VEGF) treatment.

          -  Prior chemotherapeutic treatment for metastatic colorectal cancer.

          -  Past or current history of other malignancies (with the exception of basal and
             squamous cell cancer of the skin, or in situ cancer of the cervix).

          -  Clinically significant cardiovascular disease.

          -  Current or recent daily use of aspirin (> 325 mg/day) or other non-steroidal
             anti-inflammatory drug (NSAID), or full dose anticoagulants.